Medivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on Friday
/PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...